{"schema_version":"1","generated_at":"2026-11-05T14:14:39.254Z","data_as_of":null,"url":"https://www.findmykol.com/kol/alexander-philipovskiy","json_url":"https://www.findmykol.com/kol/alexander-philipovskiy/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"alexander-philipovskiy","name":"Alexander Philipovskiy","credential":"MD, PhD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Lake Mary","state":"FL","region":{"label":"Southeast","url":"https://www.findmykol.com/region/southeast"}},"identifiers":{"npi":"1598074544","orcid":"0000-0002-7065-9578","openalex":"A5020791170"},"summary":"Alexander Philipovskiy is an Oncology physician. OpenAlex indexes 79 publications with 620 citations (h-index 14); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":79,"cited_by_count":620,"h_index":14,"latest_activity_year":2026,"source":"works"},"trials":{"count":1,"shown":3,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT06257758","title":"A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors","phase":"PHASE1/PHASE2","status":"TERMINATED","role":"Overall official","sponsor":"Valerio Therapeutics","source_url":"https://clinicaltrials.gov/study/NCT06257758","trial_url":"https://www.findmykol.com/trial/NCT06257758"},{"nct":"NCT04362462","title":"Molecular Profiling After Neoadjuvant Chemotherapy for Triple-negative Breast Cancer","status":"UNKNOWN","role":"Overall official","sponsor":"Texas Tech University Health Sciences Center, El Paso","source_url":"https://clinicaltrials.gov/study/NCT04362462","trial_url":"https://www.findmykol.com/trial/NCT04362462"},{"nct":"NCT03144037","title":"Adherence of Hispanic / Latina Breast Cancer - Patients to Adjuvant Aromatase Inhibitors","status":"COMPLETED","role":"Overall official","sponsor":"Texas Tech University Health Sciences Center, El Paso","source_url":"https://clinicaltrials.gov/study/NCT03144037","trial_url":"https://www.findmykol.com/trial/NCT03144037"}],"source":"trials"},"payments":{"company_count":52,"program_years":{"first":2021,"last":null},"rows_total":127,"shown":3,"withheld":124,"rows":[{"payer":"BeiGene","program_year":2025,"amount_usd":206709.5,"payment_count":20,"source_url":"https://openpaymentsdata.cms.gov/search?query=1598074544"},{"payer":"Eli Lilly","program_year":2025,"amount_usd":196667.01,"payment_count":4,"source_url":"https://openpaymentsdata.cms.gov/search?query=1598074544"},{"payer":"BeOne Medicines","program_year":2025,"amount_usd":184170.14,"payment_count":44,"source_url":"https://openpaymentsdata.cms.gov/search?query=1598074544"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1598074544","source":"payments"},"prescribing":{"data_year":2024,"areas_total":4,"areas_shown":3,"areas":[{"area":"Sensory organs","share_pct":56.5,"classes_total":1,"classes":[{"class":"Corticosteroid","setting":"administered","share_pct":56.5,"drugs":[{"name":"Dexamethasone sodium phosphate","share_pct":100}],"max_beneficiaries":14}]},{"area":"Metabolism & gastrointestinal","share_pct":41,"classes_total":2,"classes":[{"class":"Serotonin-3 Receptor Antagonist","setting":"administered","share_pct":39.9,"drugs":[{"name":"Palonosetron hcl","share_pct":100}],"max_beneficiaries":11},{"class":"Corticosteroid","setting":"prescribed","share_pct":1.1,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":null}]},{"area":"Nervous system","share_pct":1.4,"classes_total":2,"classes":[{"class":"Phenothiazine","setting":"prescribed","share_pct":0.8,"drugs":[{"name":"Prochlorperazine Maleate","share_pct":100}],"max_beneficiaries":null},{"class":"Gabapentinoids","setting":"prescribed","share_pct":0.6,"drugs":[{"name":"Pregabalin","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":100,"facility_pct":0},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"First-in-human trial of BH-30643, a novel macrocyclic, non-covalent, mutant-selective OMNI-EGFR inhibitor, in EGFR -mutant ( EGFR m) NSCLC.","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.3014","status":"verified"},{"title":"A phase 1/2 study of MRT-2359, a highly selective oral GSPT1 molecular glue degrader (MGD), in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) harboring AR ligand binding domain (LBD) mutations.","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.7_suppl.161","status":"verified"},{"title":"Exposure–response (E–R) analyses of efficacy and safety with raludotatug deruxtecan (R-DXd), a CDH6-directed antibod-drug conjugate (ADC), to inform dose selection for phase (Ph) 3 development in platinum-resistant ovarian cancer (PROC).","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5570","status":"verified"},{"title":"Biomarker analysis of cadherin 6 and folate receptor alpha (FRα) expression, and raludotatug deruxtecan (R-DXd) antitumor activity by FRα status, in patients with platinum-resistant ovarian cancer from REJOICE-Ovarian01 and a first-in-human Phase 1 study of R-DXd","year":2026,"journal":"Gynecologic Oncology","source_url":"https://doi.org/10.1016/j.ygyno.2026.01.727","status":"verified"},{"title":"Population pharmacokinetic analysis of raludotatug deruxtecan (R-DXd), a cadherin 6 (CDH6)–directed antibody–drug conjugate (ADC), in patients (pts) with advanced ovarian cancer (OC) or renal cell carcinoma (RCC).","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5571","status":"verified"}],"source":"works"},"contact":{"address_1":"805 CURRENCY CIR","city":"Lake Mary","state":"FL","zip":"327462115","phone":"407-804-6133","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1598074544","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":124,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2026-02-06","provider_certified":"2026-02-06","collected_at":"2026-11-04T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}